The process determines the anticipated decrease in blood glucose levels resulting from one unit of rapid-acting insulin. It is a key component of personalized insulin therapy, allowing individuals with diabetes to adjust insulin dosages based on current glucose readings. For example, if a calculation indicates that one unit lowers blood sugar by 50 mg/dL, and an individual’s glucose is 200 mg/dL above their target, they would administer four units to return to their desired range.
This value empowers individuals to proactively manage hyperglycemia, reducing the risk of both short-term complications, such as ketoacidosis, and long-term complications associated with sustained elevated blood glucose levels. Historically, fixed-dose insulin regimens were common, but this individualized approach enables more precise control and improves glycemic outcomes. Its utilization can lead to increased confidence in self-management and an improved quality of life.
